Form 4: RA Capital Boosts Climb Bio Stake with $3.50 Share Purchase

RA Capital Management, L.P. and its affiliated funds reported the purchase of 7,111 shares of Climb Bio, Inc. common stock at a weighted average price of $3.50 per share.

Summary

• RA Capital Management, L.P., along with several affiliated funds (RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P.), and a separately managed account, acquired 7,111 shares of Climb Bio, Inc. common stock.
• The transaction occurred on January 5, 2026, at a weighted average price of $3.50 per share, with prices ranging from $3.495 to $3.50.
• Following this transaction, RA Capital Management, L.P. and its affiliates beneficially own a total of 11,300,939 shares of Climb Bio, Inc. common stock.
• The beneficial ownership is distributed among RA Capital Healthcare Fund, L.P. (3,403,429 shares), Sera Medicines, LLC (2,479,872 shares), RA Capital Nexus Fund, L.P. (1,226,497 shares), RA Capital Nexus Fund II, L.P. (483,679 shares), RA Capital Nexus Fund III, L.P. (2,866,375 shares), and a separately managed account (841,087 shares).
• RA Capital Management, L.P. and its related entities are identified as both a Director (through Dr. Andrew Levin) and a 10% Owner of Climb Bio, Inc.

Sentiment

Score: 7

Explanation: The purchase of additional shares by a significant institutional investor and director indicates continued confidence in the company's prospects, which is generally a positive signal for the market.

Positives

• The purchase of additional shares by a significant institutional investor and director, RA Capital Management, L.P., signals continued confidence in Climb Bio, Inc.'s future prospects.
• Insider buying can often be interpreted as a positive indicator by the market, suggesting that those with intimate knowledge of the company believe the stock is undervalued or has strong growth potential.

Future Outlook

The filing is a transactional report and does not contain explicit forward-looking statements or guidance from Climb Bio, Inc. or RA Capital Management, L.P. regarding the company's future performance.

Management Comments

• RA Capital Management, L.P., its general partner, the various funds, Dr. Peter Kolchinsky, and Mr. Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Industry Context

RA Capital Management is a prominent healthcare and life sciences investment firm. Their continued investment in Climb Bio, Inc. suggests ongoing belief in the company's potential within the biotechnology or pharmaceutical sector, aligning with broader trends of specialized investment in innovative healthcare companies.

Related Party Transactions

• The reported transaction involves the purchase of common stock by RA Capital Management, L.P. and its affiliates, which are identified as a 10% owner and have a director on Climb Bio, Inc.'s board, making this an insider or related party transaction.

Stakeholder Impact

• Shareholders may view this insider buying as a positive signal, potentially increasing confidence in the company's stock.
• The continued investment by a major institutional holder like RA Capital Management, L.P. could reinforce the company's strategic direction and long-term viability.

Key Dates

Recommendation

The acquisition of additional shares by a significant institutional investor and director, RA Capital Management, L.P., signals strong insider confidence in Climb Bio, Inc.'s future performance. This direct investment, even if relatively small, suggests a positive outlook from a well-informed party, making the stock a potential 'buy' for investors seeking to align with insider sentiment.

Keywords

Climb Bio, CLYM, RA Capital Management, Insider Buying, Stock Purchase, Form 4, Beneficial Ownership, Healthcare Investment, Biotechnology